Enable JavaScript to visit this website.

Adherence

Help reduce the risk of MenB

You have taken a first step to help protect your child against MenB, an uncommon but potentially deadly disease.1,2

Ensure your teen completes all recommended doses of TRUMENBA to help protect them against MenB

Enroll in the REMEMBER TRUMENBA Program and receive text reminders for the next dose.

 

Please provide the information requested below to receive useful reminders on when you should schedule your child's upcoming vaccination.

*Required field.

I would like to enroll in the REMEMBER TRUMENBA Program and receive dosing reminders*:

(See terms below and at http://bit.ly/TruTC; message and data rates may apply)

To ensure that the messages are provided according to the appropriate dosing schedule, please provide the date of your child's first vaccination and choose the dosing schedule recommended by your child's health care provider or pharmacist*:

Mobile Terms and Conditions: By checking the box for text messages, you agree to receive autodialed text messages from or on behalf of Pfizer at the telephone number(s) that you provide. You understand that this is not a condition of purchase or use of TRUMENBA or of any Pfizer product or service.

  • There is no fee payable to Pfizer to receive text messages; however, your carrier’s message and data rates may apply
  • Data obtained from you in connection with your registration for, and use of, this SMS service may include your phone number, related carrier information, and elements of pharmacy claim information and will be used to administer this program and to provide program benefits such as dosing reminders, program updates and alerts
  • Pfizer will not be liable for any delays in the receipt of any SMS messages as delivery is subject to effective transmission from your network operator. T-Mobile is NOT liable for delayed or undelivered messages.
  • Pfizer reserves the right to rescind, revoke, or amend the REMEMBER TRUMENBA Program without notice at any time
  • You may receive up to 10 messages a month. Pfizer’s privacy policy is available at www.pfizer.com/general/privacy. You may unsubscribe from the Program at any time by texting STOP to 37500. For help, text HELP.

Pfizer understands that your personal and health information are private. The information you provide will only be used by Pfizer and parties acting on its behalf to send you the materials you requested and other helpful information and updates on TRUMENBA, as well as related treatment, products, offers, and services.

REFERENCES
  1. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  2. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607.
map icon

Find TRUMENBA near you

arrowUse my current location Find it! Oops! Please enter a valid ZIP code
locator icon
TRUMENBA offers a vaccine reminder program

Sign up to help ensure your teen or young adult gets all recommended doses.

Get text reminders
IMPORTANT SAFETY INFORMATION
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
INDICATION
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

Back to top